REPOSITIONING INTELLIGENCE — EVIDENCE REPORT
============================================
Generated: Nov 12, 2026, 11:44 PM UTC

DISCLAIMER: This report is for research and informational use only.
It is NOT medical advice, diagnosis, or treatment guidance.

DRUG–DISEASE PAIRING
--------------------
Drug:     Sildenafil
Disease:  Pulmonary Arterial Hypertension
Target:   Phosphodiesterase-5

EVIDENCE GRADE: Approved
Confidence Score: 94%
Evidence Level: Level 1 (RCT + regulatory approval)
Trial Phase: Phase III

MECHANISM
---------
PDE5 inhibition elevates pulmonary cGMP, reducing pulmonary vascular resistance.

OUTCOMES
--------
Improved 6-minute walk distance and hemodynamics; FDA approved as Revatio.

AI SUMMARY (generated March 15, 2026)
-----------
Sildenafil is an established, FDA-approved therapy for PAH with robust Phase III evidence. This is a validated repurposing success from erectile dysfunction research to pulmonary vascular disease.

KNOWN RISKS
-----------
• Hypotension (especially with nitrates)
• Headache and flushing
• Visual disturbances
• Priapism (rare)

CITATIONS
---------
[PUBMED] 12925463: Sildenafil for treatment of lung fibrosis and pulmonary hypertension
  https://pubmed.ncbi.nlm.nih.gov/12925463/

[CLINICALTRIALS] NCT00033314: Sildenafil in pulmonary arterial hypertension (SUPER-1)
  https://clinicaltrials.gov/study/NCT00033314

[FDA] 021845: Revatio (sildenafil) FDA approval
  https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021845

PUBMED IDs: 12925463
CLINICAL TRIAL IDs: NCT00033314

LAST VERIFIED: June 25, 2026
LAST UPDATED:  June 25, 2026
REVIEW STAGE:  published

---
Repositioning Intelligence Platform · Research Mode